IntelGenx’s (TSX-V:IGX) (OTCQX:IGXT) Montelukast VersaFilm program received positive and constructive feedback from the scientific community at the 14thInternational Conference on Alzheimer’s & Parkinson’s Diseases (ADPD) in Lisbon, Portugal.
The poster presentations were made in collaboration with professor Ludwig Aigner’s group at the Paracelsus Medical University in Salzburg. The first poster presented a preclinical study of montelukast in an Alzheimer’s disease (AD) mouse model, which demonstrated that montelukast improved learning behavior and a trend toward better long-term memory at higher doses.
In addition, the study suggested that montelukast might increase the population of beneficial microglia, distant from amyloid plaques, in a potentially novel mode of action.
The second poster presentation provided a background summary of IntelGenx’ Phase 2a study of Montelukast VersaFilm in AD patients that is currently ongoing across nine Canadian research sites.
“We have had glowing feedback from respected leaders in the AD community, as well as interest from the U.S. National Institutes of Health, which we believe would be supportive of future clinical trials in the United States,” Horst Zerbe, IntelGenx’ president and CEO, said in a statement.
IntelGenx’ Phase 2a proof of concept study will assess Montelukast VersaFilm in mild to moderate AD patients. IntelGenx expects to enroll approximately 70 subjects to evaluate montelukast buccal film following daily dosing for 26 weeks.
